Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer

Core Viewpoint - Shuttle Pharmaceuticals Holdings, Inc. has filed a provisional patent application for "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," which is a significant step in advancing its diagnostic and therapeutic programs for prostate cancer [1][7]. Company Overview - Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company founded in 2012, focused on improving outcomes for cancer patients treated with radiation therapy [8]. - The company aims to develop therapies that maximize the effectiveness of radiation therapy while minimizing side effects, thereby improving cancer cure rates and patient quality of life [8]. Research and Development - The provisional patent application is part of the company's efforts to create highly specific and effective theranostic agents for metastatic castration-resistant prostate cancer, utilizing PSMA ligands for accurate imaging and targeted therapy delivery [1][7]. - The collaboration with Dr. Alan Kozikowski, a pioneer in PSMA targeting, has been instrumental in the development of these therapeutic agents [2][5]. Market Potential - The global PSMA PET imaging market was valued at $1.5 billion in 2022 and is projected to reach$2.0 billion by 2030, indicating significant growth potential in this area [7]. - The targeted radiopharmaceutical treatment Pluvitco® for PSMA-positive metastatic prostate cancer is expected to have a market size of $2 billion [7]. Diagnostic Initiatives - Shuttle Diagnostics, a subsidiary of Shuttle Pharmaceuticals, is focused on developing pretreatment diagnostic blood tests for prostate cancer patients, including the PSMA-B ligand and the PC-Rad test [4]. - Currently, there are no available tests on the market that can predict treatment success for prostate cancer specifically [4]. Scientific Collaboration - The company has collaborated with Dr. Kozikowski and other researchers to discover novel PSMA ligands aimed at enhancing the targeting of prostate cancer cells [5][6]. - The research into antibody-drug conjugates (ADCs) and the advantages of smaller PSMA targeting ligands for drug delivery is a promising area of exploration [3].